1. Home
  2. AIDX vs DRMA Comparison

AIDX vs DRMA Comparison

Compare AIDX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 20/20 Biolabs Inc. Common Stock

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$0.62

Market Cap

6.7M

Sector

Health Care

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

N/A

Current Price

$1.46

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIDX
DRMA
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
5.6M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
AIDX
DRMA
Price
$0.62
$1.46
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
86.3K
478.7K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
34.48
N/A
EPS
N/A
N/A
Revenue
$2,045,133.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
16.71
N/A
52 Week Low
$0.40
$0.95
52 Week High
$14.09
$6.22

Technical Indicators

Market Signals
Indicator
AIDX
DRMA
Relative Strength Index (RSI) 62.70 59.20
Support Level $0.52 $1.11
Resistance Level $0.70 $1.62
Average True Range (ATR) 0.06 0.17
MACD 0.02 0.03
Stochastic Oscillator 86.29 75.76

Price Performance

Historical Comparison
AIDX
DRMA

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: